RxDoctor Payments Data

Anthony Rehil-Crest, MD

Internal Medicine · Coeur D Alene, IDNPI 1114152980

Payments from drug & device makers

$278in general payments, 2019–2025

Across 17 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$74
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • AbbVie$24
  • Kyowa Kirin, Inc.$21
  • Corcept Therapeutics$20
  • Sanofi-aventis U.S. LLC$18
  • plus $91 from 6 others

What the payments were for

  • Food & beverage$278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$278 in reported general payments places this provider in the 75th percentile of 289 internal medicine providers in Idaho.

See all internal medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$1,964
Medicare patients
101
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$85,399
TrulicityDulaglutide26$36,743
EliquisApixaban40$36,637
JardianceEmpagliflozin30$36,056
XareltoRivaroxaban26$31,386
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,129
Tresiba Flextouch U-200Insulin Degludec20$14,731
Tresiba Flextouch U-100Insulin Degludec20$10,745
MyrbetriqMirabegron23$10,450
Combivent RespimatIpratropium/Albuterol Sulfate11$6,402
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl34$6,160
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$5,072
Atorvastatin Calcium482$4,315
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen224$3,935
Gabapentin139$2,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$85,39951 claims
Lilly USA, LLCTrulicity$13$36,74326 claims
Johnson & JohnsonXarelto$74$31,38626 claims
GSKTrelegy Ellipta$18$16,12916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 289 internal medicine providers in Idaho.

Other internal medicine in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →